HUE21880926T1 - Készítmény és eljárás rák kezelésére, amely egy oltóanyagot alkalmaz elsõ terápiás hatóanyagként egy második hatóanyaggal kombinálva - Google Patents

Készítmény és eljárás rák kezelésére, amely egy oltóanyagot alkalmaz elsõ terápiás hatóanyagként egy második hatóanyaggal kombinálva

Info

Publication number
HUE21880926T1
HUE21880926T1 HUE21880926A HUE21880926A HUE21880926T1 HU E21880926 T1 HUE21880926 T1 HU E21880926T1 HU E21880926 A HUE21880926 A HU E21880926A HU E21880926 A HUE21880926 A HU E21880926A HU E21880926 T1 HUE21880926 T1 HU E21880926T1
Authority
HU
Hungary
Prior art keywords
active ingredient
vaccine
composition
combination
treating cancer
Prior art date
Application number
HUE21880926A
Other languages
English (en)
Inventor
Tim Ioannides
Evangelos Badiavas
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/068,087 external-priority patent/US11813329B2/en
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of HUE21880926T1 publication Critical patent/HUE21880926T1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE21880926A 2020-10-12 2021-10-12 Készítmény és eljárás rák kezelésére, amely egy oltóanyagot alkalmaz elsõ terápiás hatóanyagként egy második hatóanyaggal kombinálva HUE21880926T1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17/068,087 US11813329B2 (en) 2014-10-24 2020-10-12 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
HUE21880926T1 true HUE21880926T1 (hu) 2024-04-28

Family

ID=81208565

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21880926A HUE21880926T1 (hu) 2020-10-12 2021-10-12 Készítmény és eljárás rák kezelésére, amely egy oltóanyagot alkalmaz elsõ terápiás hatóanyagként egy második hatóanyaggal kombinálva

Country Status (16)

Country Link
EP (1) EP4225351A1 (hu)
JP (1) JP2023546073A (hu)
KR (1) KR20230117106A (hu)
AU (1) AU2021360676A1 (hu)
CA (1) CA3195478A1 (hu)
CO (1) CO2023006083A2 (hu)
CY (1) CY20232200001T2 (hu)
DE (1) DE21880926T1 (hu)
DK (1) DK4225351T1 (hu)
ES (1) ES2962700T1 (hu)
FI (1) FI4225351T1 (hu)
HU (1) HUE21880926T1 (hu)
IL (1) IL302098A (hu)
MX (1) MX2023004285A (hu)
PL (1) PL4225351T1 (hu)
WO (1) WO2022081604A1 (hu)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
CA2871774C (en) * 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US10799574B2 (en) * 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EA201891965A1 (ru) * 2016-04-01 2019-04-30 Кайт Фарма, Инк. Химерные рецепторы антигенов и т-клеточные рецепторы и способы их применения
WO2017177137A1 (en) * 2016-04-07 2017-10-12 Bluebird Bio, Inc. Chimeric antigen receptor t cell compositions

Also Published As

Publication number Publication date
DK4225351T1 (da) 2023-10-23
IL302098A (en) 2023-06-01
JP2023546073A (ja) 2023-11-01
ES2962700T1 (es) 2024-03-20
KR20230117106A (ko) 2023-08-07
FI4225351T1 (fi) 2023-10-20
WO2022081604A1 (en) 2022-04-21
CY20232200001T2 (el) 2024-02-16
MX2023004285A (es) 2023-06-19
PL4225351T1 (pl) 2023-12-11
DE21880926T1 (de) 2024-01-11
CA3195478A1 (en) 2022-04-21
AU2021360676A1 (en) 2023-06-15
CO2023006083A2 (es) 2023-08-18
EP4225351A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
EP4097122A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
NZ631144A (en) Compositions and methods for transmucosal absorption
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2008103690A3 (en) Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using pdgf and a bone matrix
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
IL291601A (en) Neoglycoconjugates as vaccines and therapeutic tools
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
BR112018002530A2 (pt) combinações e usos e tratamentos destas
EP4101472A4 (en) ANTI-MEFLIN ANTIBODIES FOR USE IN THE TREATMENT OF CANCER IN A PERSON WITH CANCER AND PHARMACEUTICAL COMPOSITION CONTAINING SAID ANTIBODY
WO2022012635A9 (zh) 一种药物组合物及其用途
HUE21880926T1 (hu) Készítmény és eljárás rák kezelésére, amely egy oltóanyagot alkalmaz elsõ terápiás hatóanyagként egy második hatóanyaggal kombinálva
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
IL312286A (en) Topical compounds and methods for photodynamic therapy
EP4054695A4 (en) SYSTEM AND MINIATURE DEVICES FOR THE ADMINISTRATION OF A THERAPEUTIC CONSTITUENT AT A TREATMENT SITE IN A PATIENT
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.
EP3838270A4 (en) SYNERGISTIC PHARMACEUTICAL COMPOSITION WITH ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALIZED FORMS OF RHEUMATIC DISEASES
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
SG11201907400YA (en) Method for treating myopia and application in preparation of medicament
GB202201935D0 (en) Methods and compositions for treating cancer in taxane-resistant patients